Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
Trial ID or NCT#
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToMeredith Mills
Go Back To The Trial